Novartis Buys into New Pharma World Order
In paying $5.1 billion for vaccine maker Chiron, Novartis is pursuing a unique business strategy which recognizes the growing role of governments, both as purchasers and as price-setters. The same strategy assumes, too, that pharma must seek alternative growth sources to branded prescription drugs.
You may also be interested in...
The company has hired a high-profile professor with a nose for virus sleuthing as its new ID chief, and it will start shifting its 120-member R&D staff from the Boston area next year.
As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.
Commercial production at North Carolina facility supported by the HHS grant is at least three years away.